Illumina is a leading company focused on genomic analysis, providing advanced tools and services for the study of genetic material in life sciences and clinical laboratories. Established in 1998 in San Diego, California, Illumina generates over 90% of its revenue from sequencing instruments, consumables, and related services. Its high-throughput technology facilitates whole genome sequencing for humans and large organisms, while its lower throughput tools cater to applications like viral and cancer tumor screening. Additionally, Illumina offers microarrays for cost-effective genetic screening, primarily in consumer and agricultural sectors. The company emphasizes collaboration and rapid delivery of innovative solutions, which are essential for advancing personalized medicine. Through initiatives like Illumina Accelerator, established in 2014, the company supports startups in the genomic industry by providing mentorship, financial assistance, and access to essential resources, fostering a dynamic ecosystem for innovation in genomics.
Terrapeutics Pharma specializes in drug discovery, utilizing an innovative platform that screens for therapeutic molecules derived from soil. This technology is grounded in the principles of nature, allowing for the identification of small therapeutic molecules aimed at addressing challenging medical targets. The company's focus includes the development of inhibitors for the ascending reticular activating system (RAS), as well as advancing drug discovery for infectious diseases. Through this approach, Terrapeutics aims to provide healthcare professionals with effective tools for combating various health challenges.
Dama Health specializes in pharmacogenetic technology aimed at providing personalized contraception recommendations for women and clinicians. The company employs genetic testing and an automated matching system that considers individual preferences, medical history, and specific requirements. By analyzing unique predispositions and the efficacy and side effect profiles of various contraceptive options, Dama Health enables women and healthcare providers to make informed and safe birth control decisions tailored to each individual's needs.
Nusantics, a biotechnology company, analyzes microbiome profiles. It offers microbiome profiles for skincare, personal care, food, and beverage industries. The company was founded in 2019 and is based in Jakarta, Indonesia.
Neurolytic Healthcare Ltd. is a company based in Oxford, United Kingdom, specializing in the design, development, manufacturing, and delivery of digital and genomic-based diagnostic tools and medical devices aimed at treating migraine and related neurological disorders. Established in 2016, the company focuses on personalized medicine by integrating genetic and biomarker data to enhance diagnostic accuracy and assist clinicians in determining optimal treatment strategies. Its product offerings include a diagnostic support tool, a pharmacogenetic test, and a mobile application designed for predicting migraine events. Through these innovative solutions, Neurolytic Healthcare aims to improve the management and treatment of neurological conditions.
Rethink Bio is a synthetic biology company from India, is focused on harnessing the potential of microalgae to develop sustainable food solutions to benefit the planet and people.
4SR Biosciences Inc. is a diagnostics and therapeutics company emerging from the University of Chicago that focuses on developing innovative tRNA-based modalities for identifying disease biomarkers and advancing cancer therapeutics. The company employs a proprietary platform that utilizes RNA sequencing technology to analyze cellular tRNA, its fragments, and modifications derived from various clinical samples, including tissue, biofluids, and nasal swabs. This approach allows researchers to assess and compare the biological properties of numerous microbes with distinct tRNA genes, facilitating early detection of cancer. Through its work, 4SR Biosciences aims to contribute significantly to the fields of diagnostics and treatment in oncology.
Purpose Health, Inc. a mental wellness company from Northern Virginia, supports consumers on their mental wellness journey with data-driven insights into the physiological impact of stress on the microbiome and body.
NonExomics integrates genomics, transcriptomic, and proteomics data by utilizing proprietary machine learning approaches to predict structures of nonexomic proteins and identifies disease-specific nonexomic targets, allowing clients to find cures for rare diseases.
B4X, INC., a therapeutics and diagnostics company from Atlanta, Georgia, is utilizing multi-omic big data anchored in genomics to deliver life-saving therapeutics and precision diagnostics to individuals suffering from debilitating diseases of the brain.
Cache is a biotechnology company focused on developing a groundbreaking wet operating system designed for the storage, access, and computation of biomolecules at scale. By ensuring the integrity and fidelity of nucleic acids from various sources, Cache enables researchers and partners to accelerate molecular pathology research and gain insights into life sciences. This innovative approach facilitates the analysis of biomolecules, thereby unlocking new precision medicine applications and enhancing the capacity for understanding biological data. Ultimately, Cache aims to make both digital and biological data universally accessible and sustainable, eliminating the need for data deletion or disposal.
NewStem is a biotechnology company based in Jerusalem that focuses on enhancing the effectiveness of chemotherapy through its innovative precision-medicine technology. As a spinoff of Yissum, The Technology Transfer Company of The Hebrew University, NewStem has developed a platform that predicts patients' resistance to chemotherapy, allowing for more targeted and effective cancer treatments. The company leverages bioinformatics-based software to support medical researchers in advancing regenerative medicine, disease therapy, and cancer research. By addressing the challenges of chemotherapy resistance, NewStem aims to improve patient outcomes and transform cancer treatment methodologies.
EpiCombi.AI is a genomics signature-driven therapeutics spinout from Oxford University, is overcoming epigenetic barriers in cancer complexity through the creation of AI-derived, network-acting multi-targeted drugs.
Genegoggle is a precision medicine biotech company with the goal of discovering novel therapeutics and intelligent systems to improve human health by leveraging multi-dimensional genomic and epigenetic elements.
Solena is a biotechnology company that focuses on the agriculture industry for the benefit of producers. The company providing security and confidence to farmers through an advisory service and monitoring of their crops, accompanied by the biological and organic inputs, providing efficient and timely solutions. It aims to change the way farmers use their important resources. By giving them the capability of understanding and modify its Soil's Health in order to create a more profitable Biological Capital. It works to create a world of agriculture in harmony with nature.
ImYoo Inc., a direct-to-consumer single-cell transcriptomics company from the California Institute of Technology, aims to deliver personalized, biology-driven health insights by connecting people with similar immune profiles to share their health journeys.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Developer of a cloud-based platform designed to improve cancer treatment through the prediction of patients' responses. The company's platform identifies optimal treatment for an individual, reduces treatment resistance, and offers patient-specific cancer progression and evidence-based personalized treatment plans, enabling users to proactively adapt treatment before it becomes ineffective.
Doloromics is a pain therapeutics discovery company from Dallas, Texas, is building a proprietary platform for the discovery of disease-specific pain mechanisms, biomarkers, and therapeutics.
Oshun Women’s Health is an innovative diagnostics and pharmaceutical development company exclusively committed to advancing the health of women and championing awareness of their healthcare issues.
Flightpath Biosciences is a biotechnology company that develops medications to treat rare infectious diseases. The company is bridging scientific unknowns by interrogating disparate fields of biology, taking risks, innovating and deploying potentially orthogonal approaches to achieve desired outcomes. It is working with leading scientists, therapeutics, and diagnostics experts across multiple scientific disciplines within several esteemed academic institutions and government agencies to create novel, targeted solutions. The company was founded in 2019 and based in Berkeley, California.
MultiplAI Health specializes in remote preventative screening and post-treatment monitoring for complex diseases, particularly cancer. The company utilizes a liquid biopsy based on RNA sequencing and artificial intelligence to create a universal screening test that can detect various cancers from a simple blood sample. This innovative approach allows for continuous testing, making it suitable for both early detection and monitoring after treatment. By employing advanced bioinformatics and AI algorithms, MultiplAI Health's tests can analyze a vast number of biomarkers at the molecular level, facilitating large-scale screening and enabling clinicians to provide more precise prognoses and treatment plans. The remote nature of the tests not only enhances accessibility but also significantly reduces costs compared to traditional diagnostic methods.
Biotax specializes in providing advanced biological and genomic informatics solutions aimed at enhancing personalized medicine. The company focuses on microbiome genetics analysis, utilizing artificial intelligence to deliver comprehensive insights that assist healthcare providers in diagnosing and treating diseases more effectively. Founded by a team of prominent researchers, Biotax is committed to improving patient outcomes through the development of innovative diagnostics and treatment protocols for pharmaceutical companies, hospitals, and medical centers.
Broken String Biosciences is developing a platform of novel sequencing tools to assess genome stability and to unlock the next generation of innovative medicines, including cell and gene therapies.
Parallel Health is a skin microbiome company from the SF Bay Area, aims to revolutionize skin and body care by providing deep insights and true personalization through best-in-class testing and targeted microbial formulations.
Grail, Inc. is a healthcare company dedicated to developing innovative technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, the company has created Galleri, a blood test designed for asymptomatic individuals over 50 years old, which identifies various types of cancer at early stages. In addition to Galleri, Grail is developing a diagnostic aid called DAC to accelerate the diagnostic process for patients with a clinical suspicion of cancer. The company is also working on tests for minimal residual disease and other post-diagnostic applications. Through high-intensity sequencing and population-scale clinical trials, Grail aims to advance the field of cancer screening and improve patient outcomes.
Enancio SAS, founded in 2017 and based in Cesson-Sévigné, France, specializes in genomic data compression software. Its primary product, Lena, enhances the speed and efficiency of next-generation sequencing (NGS) analyses while reducing storage costs and minimizing internal network traffic. The software is designed to maintain data integrity during compression and decompression processes, making it a valuable addition to existing informatics solutions in the field. As of July 2020, Enancio operates as a subsidiary of Illumina, further strengthening its position in the genomics industry.
Bluebee Holding B.V., based in Rijswijk, the Netherlands, develops a cloud-based genomics analysis platform that accelerates the processing of sequencing data. Founded in 2011, the company provides solutions for research centers, sequencing service providers, clinical labs, and kit providers, enabling them to manage, process, and share large volumes of genomic data efficiently and affordably. The platform is designed to address the challenges posed by the rapid advancements in next-generation DNA sequencing technology, offering high-performance computing and clinical-grade security. By facilitating faster data processing and deep analytics, Bluebee aims to enhance the implementation of whole genome diagnostics in clinical settings, ultimately supporting the development of personalized treatments and innovative healthcare solutions. As of June 2020, Bluebee operates as a subsidiary of Illumina, Inc.
Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
Grail, Inc. is a healthcare company dedicated to developing innovative technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, the company has created Galleri, a blood test designed for asymptomatic individuals over 50 years old, which identifies various types of cancer at early stages. In addition to Galleri, Grail is developing a diagnostic aid called DAC to accelerate the diagnostic process for patients with a clinical suspicion of cancer. The company is also working on tests for minimal residual disease and other post-diagnostic applications. Through high-intensity sequencing and population-scale clinical trials, Grail aims to advance the field of cancer screening and improve patient outcomes.
Edico Genome Inc. develops bioinformatics processor chip that helps in DNA analysis. It offers DRAGEN bio-IT processor, a sequencing bioinformatics application-specific integrated circuit that is integrated on a PCIe form-factor card and is provided with accompanying software as a Platform-as-a-Service that is integrated directly into sequencing instruments and next-generation sequencing bioinformatics servers. The company was founded in 2013 and is based in La Jolla, California. As of May 14, 2018, Edico Genome Inc. operates as a subsidiary of Illumina, Inc.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
Helixis
Venture Round in 2018
Helixis, Inc. is a company that develops low-cost molecular diagnostic products.
Biome Makers Inc. is a biotechnology company based in San Francisco, California, founded in 2015. The company specializes in understanding and identifying microbiomes, particularly in the context of agriculture. By utilizing DNA sequencing technologies and proprietary Intelligent Computing systems, Biome Makers provides detailed, crop-specific insights and recommendations to enhance agricultural production and product quality. Their technology enables growers and manufacturers to analyze soil ecosystems effectively, offering data-driven insights that facilitate improved decision-making in farming practices.
Trace Genomics, Inc. specializes in developing artificial intelligence-based diagnostic tools for farmers, focusing on soil health and crop quality. The company offers a soil microbiome test that utilizes DNA sequencing and artificial intelligence to analyze microbial species in agricultural soils. By interpreting key indicators of soil health and disease risk, Trace Genomics enables early predictions of soil diseases, benefiting agronomists and their corporate partners. Founded in 2015 and headquartered in Burlingame, California, with an additional office in Ames, Iowa, Trace Genomics aims to enhance agricultural practices and maximize the value of every acre for the farming community.
Vitagene, Inc. is a health technology company that uses genomic science and advanced technology to create a DNA-based personalization platform for healthcare. It offers customized supplements directly to patients based on their individual needs for nutrition, sleep, exercise, and supplementation. The company's algorithm analyzes extensive patient data, including genetics, blood work, and lifestyle, to generate personalized supplement regimens. Vitagene also manufactures DNA health test kits and provides health and ancestry reports that outline dietary, supplement, and exercise recommendations. Additionally, the company produces at-home COVID-19 saliva test kits. Founded in 2014 and based in San Francisco, California, Vitagene aims to empower individuals with tailored health solutions through big data and machine learning.
Grail, Inc. is a healthcare company dedicated to developing innovative technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, the company has created Galleri, a blood test designed for asymptomatic individuals over 50 years old, which identifies various types of cancer at early stages. In addition to Galleri, Grail is developing a diagnostic aid called DAC to accelerate the diagnostic process for patients with a clinical suspicion of cancer. The company is also working on tests for minimal residual disease and other post-diagnostic applications. Through high-intensity sequencing and population-scale clinical trials, Grail aims to advance the field of cancer screening and improve patient outcomes.
Vitagene, Inc. is a health technology company that uses genomic science and advanced technology to create a DNA-based personalization platform for healthcare. It offers customized supplements directly to patients based on their individual needs for nutrition, sleep, exercise, and supplementation. The company's algorithm analyzes extensive patient data, including genetics, blood work, and lifestyle, to generate personalized supplement regimens. Vitagene also manufactures DNA health test kits and provides health and ancestry reports that outline dietary, supplement, and exercise recommendations. Additionally, the company produces at-home COVID-19 saliva test kits. Founded in 2014 and based in San Francisco, California, Vitagene aims to empower individuals with tailored health solutions through big data and machine learning.
MetaMixis Inc. is a biotechnology company based in Vancouver, Canada, founded in 2012. The company focuses on developing enzymes and metabolic pathways for microorganisms that produce chemicals. MetaMixis creates biosensors that leverage natural environmental processes to detect biochemical transformations. Additionally, it screens diverse environmental DNA libraries to generate a portfolio of enzymes and pathways capable of performing specific transformations. The founding team combines expertise in synthetic biology, environmental genomics, and bioinformatics, with the goal of advancing the bioeconomy through innovative enzyme and pathway discovery. The company has also established a knowledgeable board to guide its development and growth.
NextGen Jane is a data-driven women's health company that focuses on providing insights into reproductive health through innovative diagnostic tools. Founded in 2014 and headquartered in Oakland, California, the company has developed a smart tampon system that allows users to conveniently mail in cells shed during menstruation. This patented tampon collection technology enables the analysis of diverse molecular signals from the reproductive tract, including the endometrium, cervix, fallopian tubes, and ovaries. By transforming these biological samples into digital diagnoses, NextGen Jane aims to facilitate in-depth sequencing and disease detection, empowering women to monitor their reproductive health and predict potential reproductive diseases with ease.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
GenoLogics, Inc. is a company specializing in laboratory information management systems (LIMS) designed to enhance the diagnosis and treatment of diseases. Their flagship product, BaseSpace Clarity LIMS, is utilized by research and clinical laboratories to effectively track samples from receipt to results, thereby improving accuracy, reducing costs, and ensuring high quality standards. Founded in 2002 and headquartered in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics aims to support translational medicine and systems biology initiatives through its collaborative data management software platform. As a subsidiary of Illumina, Inc., the company focuses on advancing life sciences research by facilitating early detection, prevention, and treatment of various diseases.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Biome Makers Inc. is a biotechnology company based in San Francisco, California, founded in 2015. The company specializes in understanding and identifying microbiomes, particularly in the context of agriculture. By utilizing DNA sequencing technologies and proprietary Intelligent Computing systems, Biome Makers provides detailed, crop-specific insights and recommendations to enhance agricultural production and product quality. Their technology enables growers and manufacturers to analyze soil ecosystems effectively, offering data-driven insights that facilitate improved decision-making in farming practices.
Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. The company's innovative platform identifies sequences within the human genome that regulate gene expression through advanced screening and computational methods. Its therapy pipeline targets a variety of genetic and acquired disorders across multiple disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, Encoded Therapeutics aims to enhance treatment options available to medical practitioners, ultimately improving patient outcomes and quality of life.
EpiBiome is a venture-backed precision microbiome engineering company tackling the challenge of antibiotic resistance by developing alternatives to small-molecule antibiotics for use in healthcare, veterinary and agriculture industries.
Antibiotic-resistant bacteria surpass nuclear warfare, climate change, and terrorism as the biggest challenge facing humanity today. The pipeline of new antibiotics has slowed to a trickle, while the emergence of multi-drug resistant bacteria is on an unprecedented trajectory. These bacteria threaten to reverse more than 100 years of medical progress by making all but the most necessary surgical procedures too risky due to the threat of post-operative infection.
Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012 that focuses on developing innovative technologies for cancer cell analysis and immunotherapy. The company specializes in a proprietary bench-top system that allows for the capture, growth, and analysis of primary cells directly from patient blood samples. This technology is designed to enhance the control of cell phenotype and function, thereby optimizing the efficacy and persistence of immune cell therapies. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to empower researchers with advanced tools for cell maintenance and expansion, ultimately facilitating predictive therapy development and improving clinical outcomes.
Human Longevity (HLI) is a health intelligence company focused on advancing proactive healthcare through genomic insights. Founded in 2013 and based in San Diego, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with machine learning, to enhance medical practices and foster discoveries in health. The company’s primary offerings include the HLI Health Nucleus, a clinical research center that integrates whole-genome sequencing, advanced imaging, and personalized health data to provide a detailed view of individual health. HLI also addresses significant health issues, such as cancer, diabetes, obesity, heart and liver diseases, and dementia, by leveraging DNA sequencing and expert analysis. Through its innovative approach, HLI aims to improve health outcomes and transition healthcare from reactive to proactive strategies.
NextBio is a privately owned software company based in Cupertino, California, co-founded in 2004 by Saeid Akhtari, Ilya Kupershmidt, and Mostafa Ronaghi. The company offers a platform designed for life science researchers to search, discover, and share knowledge across both public and proprietary data. This platform utilizes an ontology-based semantic framework that integrates diverse data types, including gene, tissue, disease, and compound information, into a single searchable environment. By employing proprietary algorithms, NextBio enables researchers to formulate and test hypotheses using extensive collections of experimental data. The enterprise version of the platform is utilized by major pharmaceutical companies, allowing users to upload and integrate internal data with publicly available datasets. This capability enhances researchers' ability to identify prognostic and predictive molecular signatures relevant to their studies. NextBio has received recognition for its contributions to the life sciences field, including the Frost & Sullivan North American Life Sciences Customer Value Enhancement Award in 2008, and has attracted over 1.5 million visitors since its launch.
Advanced Liquid Logic, Inc. is a company specializing in microfluidic devices for liquid handling applications, offering innovative workflow solutions for laboratories and clinics. Founded in 2004 by Dr. Michael Pollack and Dr. Vamsee Pamula, who developed the core technology during their academic research at Duke University, the company focuses on creating lab-on-a-chip devices that can be programmed to perform a variety of assay protocols, including immunoassays, polymerase chain reaction (PCR), and clinical chemistry. Under the leadership of CEO Richard West, who has a wealth of experience in business and product development, Advanced Liquid Logic aims to address unmet challenges in scientific research by providing versatile and efficient solutions in liquid handling.
Moleculo is a biotech company that focuses on developing technologies for generating long reads for genome analysis tools. The company has developed a novel DNA sequencing method that provides long and accurate reads, thereby improving the efficiency and accuracy of many existing DNA sequencing applications, enabling clients to get a range of new applications.
Verinata Health focuses on maternal and fetal health by developing non-invasive tests for the early identification of fetal chromosomal abnormalities. Utilizing proprietary technologies, the company analyzes cell-free DNA in maternal blood to offer a safe and accurate assessment of fetal aneuploidy. This approach aims to alleviate the anxiety associated with traditional prenatal screening methods that often involve multiple steps, high false-positive rates, and invasive procedures. Verinata seeks to provide women with a straightforward solution, consisting of a single blood draw that delivers definitive results. The company is also conducting a large-scale, prospective, blinded pivotal study to validate the sensitivity and specificity of its prenatal test, with results anticipated to enhance the understanding and effectiveness of prenatal care.
BlueGnome Limited specializes in developing genetic diagnostic solutions aimed at screening for chromosomal abnormalities. Based in Fulbourn, United Kingdom, the company gained recognition for its innovative approaches to genetic testing. In 2012, BlueGnome was acquired by Illumina, a leading company in the field of genomics, further enhancing its capabilities and reach in the market for genetic diagnostics.
GenoLogics, Inc. is a company specializing in laboratory information management systems (LIMS) designed to enhance the diagnosis and treatment of diseases. Their flagship product, BaseSpace Clarity LIMS, is utilized by research and clinical laboratories to effectively track samples from receipt to results, thereby improving accuracy, reducing costs, and ensuring high quality standards. Founded in 2002 and headquartered in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics aims to support translational medicine and systems biology initiatives through its collaborative data management software platform. As a subsidiary of Illumina, Inc., the company focuses on advancing life sciences research by facilitating early detection, prevention, and treatment of various diseases.
Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.
Epicentre Biotechnologies
Acquisition in 2011
Epicentre, is a manufacturer and seller of high-quality molecular biology products for life science research, clinical research, molecular diagnostics and biopharmaceutical manufacturing. Products are available for RNA amplification and gene expression analysis, transposon-based genetic analysis, DNA and RNA purification, DNA sequencing, PCR and RT-PCR amplification, DNA and RNA modifying enzymes, genomic cloning, in vitro transcription, and protein research and purification. In addition to our broad molecular biology product line, Epicentre also offers custom protein manufacturing.
Affomix is a biotechnology company specializing in the development of antibody-based products. Utilizing proprietary technology, it offers rapid and automated high-throughput selection of human monoclonal antibodies (mAbs). The company focuses on commercializing its mAbs, along with mAb microarrays and mAb libraries, for various applications in research, drug discovery, diagnostics, and therapeutics. Affomix aims to enhance the sensitivity and accuracy in measuring large numbers of proteins in biological samples, leveraging its capabilities to produce and screen antibodies against virtually all human proteins, including those that are post-translationally modified.
Helixis
Acquisition in 2010
Helixis, Inc. is a company that develops low-cost molecular diagnostic products.
Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.
Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.
Solexa
Acquisition in 2006
Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.
Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.